COX-2 inhibitors - Lessons in drug safety

New England Journal of Medicine

Volumn 352, Issue 11, 2005, Pages 1133-1135

  Psaty, Bruce M ^a   Furberg, Curt D ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; PARECOXIB; ROFECOXIB; VALDECOXIB;

ALZHEIMER DISEASE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOEMBOLISM; TREATMENT WITHDRAWAL;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOXAZOLES; LACTONES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PUBLISHING; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SULFONAMIDES; SULFONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 14944368720     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058042     Document Type: Editorial

References (14)

1. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
2. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
3. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
5. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
6. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
7. Villalba ML. FDA medical officer review of VIOXX (rofecoxib), NDA 21-042 (capsules) and NDA 21-052 (oral solution). (Accessed February 24, 2005, at http://www.fda.gov/cder/foi/nda/index. htm.)
8. Targum SL. Consultation on NDA 21-042, S-007: review of cardiovascular safety database (on Vioxx or rofecoxib). FDA memorandum, February 1, 2001. (Accessed February 24, 2005, at http://www. fda.gov/ohrms/dockets/ac/01/ briefing/3677b2_06_cardio.doc.)
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits ofestrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
10. Freedman L, Anderson G, Kipnis V, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Control Clin Trials 1996;17:509-25.
11. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
12. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-92.
13. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90.
14. Pfizer. A double-blind randomized placebo-controlled comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's disease, protocol IQ5-97-02-001. (Accessed February 24, 2005, at http://www. clinicalstudyresults.org/documents/company-study_76_0.pdf.)